Last reviewed · How we verify
RHB-105
RHB-105 is a combination of rifabutin and hyoscyamine for the treatment of COVID-19.
RHB-105 is a combination of rifabutin and hyoscyamine for the treatment of COVID-19. Used for Treatment of COVID-19.
At a glance
| Generic name | RHB-105 |
|---|---|
| Also known as | Amoxicillin, Omeprazole and Rifabutin |
| Sponsor | RedHill Biopharma Limited |
| Drug class | Antiviral combination therapy |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
RHB-105 is a combination therapy consisting of rifabutin, an antibiotic, and hyoscyamine, an anticholinergic agent. The mechanism of action is multifaceted, with rifabutin targeting the bacterial component of COVID-19 and hyoscyamine potentially reducing inflammation and modulating the immune response.
Approved indications
- Treatment of COVID-19
Common side effects
- Nausea
- Diarrhea
- Abdominal pain
Key clinical trials
- ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator (PHASE3)
- ERADICATE Hp - Treating Helicobacter Pylori With RHB-105 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RHB-105 CI brief — competitive landscape report
- RHB-105 updates RSS · CI watch RSS
- RedHill Biopharma Limited portfolio CI